Evotec SE (EVO) 2025 Q2 法說會逐字稿

Ladies and gentlemen, welcome to the Evotec SA Half year Report 2025 conference call. I am Matilda, the chorus call operator. (Operator Instructions)

The conference must not be recorded for publication or broadcast.

At this time, it's my pleasure to hand over to Volker Broun, Head of IR and ESG. Please go ahead.

Thank you, Matilda, and good morning, good afternoon to everyone in the call. Thank you for joining us today. Today, we will cover our first half, 2025 results, and we will discuss the progress we have made in the execution of our strategy, as well as the key operational and external developments.

We will, of course, also provide an update on the evolution of the just it will take biologics business of which the plants and those deal is part of. However, because of the running process, we will not dwell in the details as such. We appreciate your understanding.

Before we start, the usual thirty seconds on housekeeping items. On page 2, we share the cautionary language with you. Some statements will be future-looking based on information available today, and they might be subject to change in the future.

But now let me hand over to the CEO of Evotec, Doctor Christian Wojczewski.

Christian, please.

Good afternoon and welcome to our H1 call. In April this year, we unveiled a new strategy, a strategy that sharpens our focus on pioneering drug discovery and development. With a plan to center our business around its core technology and scientific strength. To cultivate operational excellence and to place us on the path to sustainable, profitable growth.

As we reflect on the first half of 2025, we can say with confidence that we've made meaningful progress on our journey. Our transformation efforts are on track in delivering tangible gains. Just it will take biologics remains on its strong growth path. Driven by our unrelenting focus on technology leadership and biologics.

In other areas, we're actively managing continuing market challenges. We'll talk about all of this today. To be in a position to sustainably shape the future, we are following a structured and disciplined process, and we're delivering on it. We took immediate action in 2024 when resetting parties was essential. And we're ahead of plan in achieving our cost saving targets. Paul will elaborate on this later.

In Q3 2024, we announced the launch of an in-depth strategic review, which we completed according to plan. The re-tooling of Evotec is starting to materialize.

We're strengthening our competitive position in the field of drug discovery by focused investments into our technology platforms. A great example is the expansion of our molecular patient database. And we're further evolving our business model at Just Evotec biologics.

Next on our agenda we're now aligning the organization. With our strategy This work is currently underway, and we expect it to be completed before the end of the year. Ensuring we are all well positioned to compete and perform even more effectively in the years ahead.

The core element of our new strategy is to sharpen our offer and reduce complexity. Furthermore, we're upgrading our commercial model, providing stand-alone services, integrated by discovery, and strategic partnerships.

The business segmentation and terminology of our reporting should reflect our new setup. Consequently, going forward, we will have two core business segments reported as discovery and pre-clinical development E.MPD. And just Evotec biologics JEB.

E.MPD covers our discovery and development activities for small molecules and new modalities from target identification to IND. Just Evotec Biologics is covering our large molecules business. Our vision, it's both business segments. We are unleashing innovation to enable our partners to develop life changing medicines.

Pioneering drug discovery and development for us means leveraging cutting edge technology, disruptive science, and AI driven innovation to drastically accelerate the journey from concept to cure. Let me now share with you some observations on the developments during the first 6-months of the year.

H1 has not been without its challenges. We saw a revenue decline in our discovery in preclinical development segment of 11%. A large part of that is related to a temporary effect in our BMF collaboration. The remainder is driven by continued softness in the early drug discovery market.

In the first half, we've seen higher negative change orders compared to the previous period. Most of these ex change orders are related to scientific reasons. And the impact can be volatile. In the start of the second half of this year, we're back to normalized levels of change orders.

Furthermore, since the beginning of Q2, we are seeing a steady increase in number and value of proposals going out to customers. We continue to progress well in both of our collaborations with BMS in neurology and oncology.

In Q2 we further expanded the scope of our molecular patient database by joining the Nurture Consortium. I will share the strategic rationale with you later on the call. We've initiated the rollout of the new operating model to align our organization with our strategy to simplify our segment structure, reduce management complexity and layers.

Most importantly, to increase accountability for results in all parts of the organization. This isn't just a reorganization, it's a reorientation towards both operational and science excellence. Just tech biologics continues to outperform. With 16% revenue growth year over year, JEB is not only enjoying high demand and delivering strong results above our expectations.

It is validating our vision, a vision where we shape a new segment in the biologics manufacturing market. With differentiated and scalable technology. We remain bullish about the prospects of our JEB business. At the end of July, we announced the planned sale of our to lose sight to Sandoz. This is a natural progression in the J.POD life cycle.

And it marks a major milestone in our strategy to lean into JEB's capabilities as a scalable technology provider with an asset lighter model. Now, let me spend a few words on the relevant market environment we are operating in. We're navigating a complex funding landscape in biotech. While venture capital inflows are stabilizing at pre-pandemic levels, the distribution remains uneven.

Early stage investments such as seed and series A rounds, which typically support companies with projects in discovery or pre-clinical cases, continue to lag behind later stage funding. The funding equilibrium between discovery and pre-clinical on the one side and clinical stage companies on the other has yet to be achieved.

We continue to observe a cautious spending behavior in earlier stage R&D. In contrast, clinical programs, many of which originated during the well funded pandemic years, benefit from more robust financial backing and spending.

Our customer base in biotech is mostly focused on discovery and pre-clinical research. Funding for this sector is still behind normal pre-pandemic levels, and spending behavior, therefore is more careful. Signs of a modest recovery in funding are emerging. Over the coming quarters, we expect a more normalized distribution of funding and project flow to take shape.

Let me now hand over to Paul Hitchin, our CFO to guide you through the H1 financials.

Paul, please.

Thank you, Christian, and a warm welcome from my side. Now, let me guide you through the first half results in more detail.

Our first half, 2025 group revenues reached EUR371 million a 5% decrease versus the first half of 2024, which has been impacted by two counter balancing effects. Firstly, our E.MPD revenues declined by 11% to EUR269 million in a persisting soft market, as Christian alluded to during his introduction.

Included in this result is the expected temporary decline in BMS revenues in 2025. Excluding the expected BMS revenue decline, there is a normalized year on year decline of 6% in the E.MPD segment. As I mentioned in our last call, looking forward for BMS, we have strong work packages and an excellent asset pipeline.

In contrast, just Evatech biologics has continued to grow strongly in the first half of 2025, reaching EUR102.2 million of revenue, which is up 16% versus the first half of 2024. The majority of the year-on-year growth is driven by the excellent growth of our business with non-Sandoz and DOD customers as we broaden our customer base.

Our first half, 2025 standards business grew low single digits on a strong 2024 comparative and our partnership with the DOD some saw some low value decline in revenues. Our remaining business showed an excellent growth in the first half with 87% growth versus prior year, underlining our very positive outlook for the just Evotec biologics business.

It's worth noting that amongst our growing just customer base, we have three major pharma companies who meaningfully contributed to our first half growth performance. Our R&D spending has reduced by 35% versus prior year from EUR29.3 million in the first half of EUR24 million to EUR19 million in the first half of 2025 as we direct our investments to those most relevant for our partners.

Our spending is broadly in line with our new expected run rate for the year, as we continue to focus our R&D activities. Adjusted Group EBITDA reached negative EUR1.9 million driven by stronger than expected contribution of EUR7.5 million from the Just Evotec politics business, helped by positive operating leverage, despite the just organization build out that we articulated in our April call.

The strong contribution of our Just Evotec-bios business helped offset the lower operational leverage from the soft revenues in the E.MPD segment. Despite the lower revenues in our E.MPD segment, we've only seen a moderate impact on profitability.

We are executing operationally with rigor. Our cost out initiatives are progressing well. With the initial target for the disciplined spending and hiring activities already being reached, and external spend management progressing as expected.

In addition, we have added a further recurring cost reductions, with an additional 2025 impact of around EUR10 million in the E.MPD business. This takes our 2025 cost reduction plans to over EUR60 million including the EUR30 million full year impact of the priority reset program.

Our additional measures are focused on lower external spending, higher restrictions across all of our sites. In summary, we have now reached an FTE reduction of 600 since March 2024, which is 200 FTE above the original priority reset target, and we've already realized about 50% of our updated cost out target of EUR30 million.

Continuing with our cash flows. In line with our expectations, operating cash flow further improved in the second quarter, including the expected receipts of the BMS completed work packages that we announced previously.

Investing cash flow in the second quarter of 2025 is in line with our Q1 figures and is largely driven by our CapEx spending of EUR19 million in the second quarter of 2025. Our first half of 2025 CapEx saw a 50% decline to our 2024 levels as we move towards the new CapEx base level I mentioned in the April update.

Overall, our liquidity has been developing as we expected, with a decrease of EUR223 million to EUR348 million driven by regular lease and scheduled debt payments of EUR18 million and a negative FX difference of EUR7.5 million.

Both partially compensated by positive net inflow from operating and investing activities. We have stable financing and proactive liquidity management, and following our decision to cancel our unutilized and not currently required RCF facility, our financing is no longer restricted by covenants.

Now let me hand back to Christian, who will provide an update on some of our strategic developments.

Thank you, Paul.

Let us now dive deeper into strategically important developments in both segments, E.MPD and JEB. Our commitment to technology and science leadership remains unwavering. The continued development of our moleka patient data platform E.MPD underscores our dedication to precision medicine.

Most recently, the platform was expanded to include the nurture cohort comprising approximately 3,000 patients with acute kidney injury. It's our conviction that deep understanding of molecular mechanisms based on real patient data are fundamental to accelerate the drug discovery journey and to better support our identification and validation.

What sets Evotec's E.MPD apart is the unparalleled breadth and depth of its patient-related data encompassing both high quality clinical information and a wide range of omics data. This level of quality, depth, and consistency clearly differentiates it from publicly available data sets.

With data from over 27,000 patients across chronic kidney disease, immune-mediated inflammatory diseases, and metabolic disorders, we're reinforcing our leadership in these therapeutic areas. But our ambition goes further.

Our molecular patient database has now reached critical mass, enabling us to explore disease areas beyond our initial focus. As is often the case, many patients suffer from multiple comorbidities, opening new avenues for discovery. For example, we're now identifying and validating novel targets in women's health.

Another area that has reached critical mass is obesity. One of the most active research fields in bio-pharma these days. And we're committed to systematically expanding our database to deepen disease understanding where there is both medical needs and commercial opportunity.

Our industry-leading kidney franchise exemplifies how scientific and technological leadership and drug discovery opens up business opportunities. They go far beyond traditional COO services. Expand our addressable market and significantly enhances value creation.

Evotec not only earns revenue through service fees, but also participates meaningfully in the success of partner programs via milestones and royalties. My (inaudible) alone would usually not qualify for substantial commercial upside.

The true value lies in the ability to translate data into actionable insights. This is the essence of our model, empowering others to discover and develop innovative treatments. In chronic kidney disease, we've repeatedly demonstrated our ability to scale the platform as illustrated here in this chart. And we're applying the same capabilities to diseases driven by inflammatory and immunologic mechanisms.

As our patient database continues to grow, it will serve as a catalyst for new strategic collaborations. Moving over to a large molecule business, with regard to just, it will take biologics back in April. I explained that the potential of this asset is not yet fully exploited. And that we're considering ways to better monetize our technology.

We're planning to further strengthen our intellectual property and leadership position in the continuous manufacturing process technology in cell lines, and other areas. This will allow us to enlarge our addressable market, providing access to new revenue streams and growth.

We also announced that we are pivoting towards the CapEx lighter business model, and we're not contemplating to invest into a network of J.Pods. The new strategy will significantly improve our return on [vest]. To better revenue mix with higher margin business and reduced demand for capital.

Today, a few months after our announcement, this strategy is already starting to get in shape. At just Evotec biologics, we are entering into a new area of bio-manufacturing, one defined by agility and scalability. We think that narrowing down this business model is simply a manufacturing and capacity play does not give it justice.

Just like we're developing in the next generation technology platforms for small molecules in our E.MPD business. We're also shaping the next generation CDMO model for biologics. Our customers are excited about the cutting edge features of our technology and the new degrees of freedom it offers to them to manufacture biologics.

Our goal is to enable them to bring the next generation of medicines to market faster, smarter. And more sustainably, a top quality and unrivaled efficiency. Regardless If with Evotec owned manufacturing capacity or indirectly through our technology.

Our US operations have always been and will remain the center of excellence for biologics discovery, process development and manufacturing. And that is where we will continue to innovate. In light of a deep funnel of projects with originators, we see ample opportunities to grow while we pivot towards an asset like a business model leading to a high return on investment.

Within the classic CDO market for biologics, which is characterized by a robust double-digit market growth, just as shaping the sub-segment for continuous continuous manufacturing. Technology advantages will allow this new segment to gain share over the next couple of years.

Beyond the manufacturing market, Evotec will now be able to also tap into adjacent opportunities. Such as the markets for sins and serum-free media, both expected to grow at healthy rates. Those product classes are developed in-house at just Evotec biologics.

They are today important components of an integrated or standalone offering. Together with our process technology. Given the industry leading performance of our cell lines and media, we're able to elevate the output. And efficiency of biologics manufacturing to the next level.

We're therefore comfortable that we will be able to create exciting new business opportunities beyond the classic capital intensive CDMO play. To the extent possible, let me now briefly address the recently announced agreement with our partners Sandoz.

On July 13, Evotec and Sandoz announced the signing of a non-binding agreement regarding the potential sale of just Evotec Biologics EU. Which owns the J.POD biologics manufacturing facility in Toulouse, France. And to grant access to its proprietary platform for integrated development and advanced continuous manufacturing of biologics via a technology license.

The agreement is a testament for a world-class continuous manufacturing technology. And reflects the successful progression of our strategy to leverage our capabilities. In a more capital efficient way. This step marks the natural evolution of our partnership. The site in Toulouse has been dedicated entirely to Sandoz since July 2024.

We're now progressing to the next phase in which we will hand over the site to Sandoz. While our partnership will move towards enabling Sandoz to manufacture on site and to a new revenue model. The plan transaction perfectly matches with our strategy to move toward an asset lighter -- like a higher margin business model.

One that leverages our proprietary technology scales through partnerships, removes the capacity ceiling for growth, and delivers superior returns. Through the plan transfer of our J.POD to lose facility to Sandoz, we're monetizing a world class asset while retaining the core IP, the platform capabilities, and the strategic upside.

It's the deployment of our technology at scale to a trusted partner in a way that accelerates both impact and profitability. It comprises economic benefits in the short-, medium-, and long-term, including around $300 million consideration for the site. Plus, technology, license fees, multi-year development revenues, milestones, and royalties.

What are the next steps? We have entered a phase of trustful discussions with the works council representatives. Closing of the plan transaction remains subject to completion. Of the relevant information and consultation processes with employees and their representatives, final contractual agreements and meeting regulatory requirements expected in the fourth quarter.

The planned transaction would immediately improve Evie's revenue mix, profit margins, and capital efficiency. I'm aware this call will not answer all your questions. We are informing the markets based on the release you saw on July 30. And because of the advanced stage and the materiality of the transaction.

More details will follow once we have concluded the process. Hence, we will not go into further the content of the deal today. After having adjusted our revenue guidance to keeping our EBITDA guidance unchanged in July, we confidently confirm our 4-year 2025 guidance.

Whilst foreign currency fluctuation has had an immaterial impact in the first half, we see a higher impact in the second half, which will be offset by improved business next. The main drivers of our fully adjusted EBITDA profile reflect improved cost performance. And changing revenue makes for a higher share of high margin revenues.

With regard to the mid-term outlook, the key message is we're on track. Lever for mid-term value creation remain the same. And for two out of the four, we can already share that we're making remarkable progress. As discussed, we've received validation for JEB's continuous manufacturing technology and made significant progress to a more capital efficient model that better leverage our technology.

And we had a plan in our implementation of operational excellence with further productivity improvements anticipated in the near term. Structural changes mix remain within the boundaries of our mid-term outlook. Our asset pipeline is on track with an unchanged number of six programs in clinical trial stage.

It is encouraging to see that discussions with customers translate into tangible results once the transaction with Sandoz is signed. We can confidently state that the visibility towards our mid-term goals will improve substantially.

Therefore, our 2028 aspiration remains bold but grounded, 8% to 12% revenue CAGR. And greater than 20% EBITDA margin. These are not just numbers, they are reflections of a strategic conviction. With differentiated offerings, operating leverage. And continued innovation were poised for long-term growth. It will take us on track. We're moving quickly towards a simpler, more focused organization. The team is energized, strategy is clear. We will continue to shape the future of drug discovery and development.

Let's take your questions. Thank you.

Back to the operator.

(Operator Instructions) Charles Weston, RBC Europe.

Hello, thank you for taking the questions. I have three, please. I'll just take them one at a time. On the first is in terms of your guidance for this year, you say you expect the recovery in the balance between early stage and late stage funding. How much of that recovery is built into the guide for 2025, please?

So, the statement was referring to recovery of the VC funding. We don't expect that this is translating into Second half.

Hey Charles, it's Paul, what you should, when we think about the guidance for the year on the [GP&D] business, the dynamics that we see in the first half, we are planning for similar dynamics in the second half.

Perfect, thank you. Secondly, you've divided your, R&D business into transactional, integrated and large farmer. Could you give us a kind of a breakdown proportionally of the revenues there and you've given a little bit of color in terms of what the growth would have been or the smaller contraction that would have been for the first half exceeding DMS, but could you perhaps touch on in terms of those three buckets, what the proportions are by revenue and what the current growth rates are, please?

Charles, we're not breaking this. Into details and not reporting, but, if you recall the last meeting, the last analyst called mentioned that the dynamics is such that the, transactional part, is shrinking relative to the integrated and large, partnership, portion. So, the latter part, the integrated and the strategic partnerships have been growing in size relative to the transactional over the last couple of years.

We expect this to continue also in our strategic planning. That said, I also mentioned that we want to have a more bespoke commercial set up, because we feel that we actually can also do better on the transactional side.

Okay, thank you. And just the last question, I appreciate you've been clear you're not going to provide concrete numbers on the Sandoz, the impact on the standard deal, but can you just perhaps give us some color philosophically on how we should be thinking about the value transfer. Leave a tech to Sandoz from this deal in return for that 300. So, if I'm looking at a number of years, how should I be thinking about the potential contribution from this deal post this deal compared to before, appreciating no hard numbers.

All right. So, let me, maybe, make a couple of statements first. I'm pretty sure, Paul in a second will tell you that we can't talk about it. But, a bit of context maybe because I fully expect that there will be similar questions, also after you, Charles.

So, first of all, Maybe a bit broader context here. We are executing our strategy from a position of strength. We've got a proven world-class technology at Evotec technologics. Our customers are excited about the cutting edge performance of the cell lines, the media, the processes, our development capabilities.

We are growing outside of the Sandoz and DOD business at high speed. If you maybe have called the number that Paul was mentioning 87% in the first half. So it, it's growing at fast speed. The value in our view, a majority of the value of the business sits in the technology capabilities IP people would have.

We said earlier this year that we plan to monetize this value better. You've heard us talking about licensing fields, you've heard us talking about royalties. We also said that we want to enable our partners to use the technology.

So you've heard us talking about continued revenue flows and milestone payments. And yes, we are also selling a site for which the consideration is around $300 million. So think about this, as a partnership that has been going on since long. And now we're changing a bit the parameters, but obviously, we do that because it fits perfectly with the strategy and because we think it makes economically a lot of sense.

Paul.

I think Christian, you've pretty much covered what we can say at this point in time, as Christian Riley says, the consideration of $300 million reflects the value of the site. In addition, technology consideration, future development revenues, milestones and, product royalties will be part of our ongoing, revenue streams.

Brendan Smith, TD Cowen.

Great, thanks guys for taking the questions. I wanted to actually ask a bit more about the E.MPD segment. I understand some of the funding uncertainty from Parma and, makes sense given everything going on. I'm actually wondering if you can speak just a bit more to what you're hearing in conversations there.

And even broad strokes what some of the trends are in driving those decisions, I guess does it seem to you that, customers are shifting spend toward lower risk indications or away from high risk innovation, just kind of wondering if there's anything consistent there to help us understand what could turn that around in the coming months.

Did you say large farmer or biotech? Sorry.

Both if you're able to provide it.

Well, it's probably not a secret that, right now, a biotech is pretty much down, especially when you think about US biotech and particularly East Coast US where there's a lot of business. So that has been going on for quite a while, and I think we've been all talking quarter by quarter about the tipping point.

We don't see this. We've actually provided you today with a little bit of data and statistics to underpin, maybe what has been a bit more anecdotal in the last couple of calls. But those two match. So what we see in the funding profile that, The early stage, biotech is currently not yet spending the same amount of money that it has been, clearly not during the pandemic, but also not before the pandemic. Seems to be the effect, but it's also anecdotally, what we hear from our customers.

Much more cautious decision behavior and frankly, we also see that in academics, because, you probably, know, we've got a an arm, which we call bridge where we are, helping, small businesses that come from universities, to connect with pharma companies, when we basically do the work for them in early research. It's the same pattern here.

Much more careful, decision-making and spending. When you go to pharma, I think it's Not such that you basically have one story to tell. It's not much less homogeneous. Every company is in a different stage of its life cycle. We have partners and customers who are restructuring. We've got others who are, forcefully looking into new indications and new, target identification. So that picture is a bit more, more next.

I hope that helps a little bit.

Yeah, understood, thanks. And then if I could just really quickly as actually as it relates to your AI capabilities, I know you spoke a little bit to some of the proprietary data sets you've got, I'm actually just wondering if there's been any renewed interest in leveraging this either internally or from your partners just kind of given FDA's recent push towards more of these competition modeling technologies. I'm just trying to understand maybe your strategy or applications and how it's evolved recently.

Absolutely. And thanks for the question and important topic for us. I hand this over to the court. Yeah, thank you for the question.

So generally, I would say you can definitely feel that there is a general, generally heightened interest in incorporating and including AI machine learning technologies and tools into the drug discovery process. Which, is, which means that, this is not only sort of in regards to safety assessments, largely what the FDA is alluding to, but also in the early stages, target ID validation in particular, of course, also in the drug design process, when it comes to really designing molecules and optimizing them for further development.

So, we don't, I would say at this point in time, we don't really see sort of that, there is a particular, very hard push on the front of, safety profiling because there's still sort of, a lack of data to support, especially. Safety predictions properly in a bunch of areas, but, we do see efforts of companies trying to fill this void by generating large amounts of data to build these predictive tools.

And, once again here you will take is really well positioned through our platform that, is especially geared towards Omics drug discovery, Omics is sort of more the, essentially the qualification of biology and, so we feel well positioned for this, not just to the Omics arm, but also through our own capabilities, in terms of building superior asset systems, IPSC based, etc. But also our own tools that we are developing in the house.

Thanks court, and by the way, I should mention we don't talk too much about it, but the computational chemistry is obviously since long an important component of our business anyway, so it's happening, it's not like something, fancy in the future.

Michael Riskin, Bank of America.

Great, thanks for taking the question. I was wondering if you could comment on the pricing environment you're seeing, in, among your customers, are they becoming more price sensitive? Is there increasing competition just given the, softer demand environment, I imagine, more. More CROs and research partners are, competing for some of the same bids and proposals.

Thank you, Michael. And as I mentioned already during the last call, we have to desegregate a little bit of business here. Obviously, there's a portion that is more transactional stand-alone services. There's another portion of our business where we have integrated deals and long-term strategic partnerships. As you probably will appreciate the latter part.

It's, is less of a price compensation here. It's about the value that we bring to the partners through our platforms. And given that there's a lot of IP and also, technology leadership around this, it's, hard to compete because it's not a service that you put on the shelf of a supermarket.

And the more transactional side, obviously, in an environment where, the market is more soft. It would be, inappropriate to say that this is not happening. We do see that price negotiations are different than it had been maybe two years ago. But as I said earlier, the exposure probably on our side compared to COO players who are 100% in that segment is a bit less.

Okay, and I was wondering if you could comment a little bit on, geographic, if you see anything different, from, your partners and customers in Europe versus the US versus, Asian Pacific, if there's some parts of the world that are, a little bit more cautious or maybe a little bit further along in the recovery path. Thanks.

I think it's fair to say that right now there is still a lot of traction in the market in the East, Asia, China. As opposed to, I would say the other extreme which is probably US, you're in the middle somewhere. Broad picture. So, yes, geographically, there's different behavior, different market dynamics right now.

Our exposure, as is geared towards Europe and, US, as we're probably right now not benefiting from the trends that we see in China. But, we also believe that if the market is actually returning that. We should then over proportionately benefit from the geographic recovery. Okay.

Thank you. Fynn Scherzler, Deutsche Bank.

Yes, hi, and thanks for taking my question. I have a couple of questions on the JEB business. I understand you cannot speak about the deal specifically, but maybe you can help us understand the mix of the JEB business as it stands now.

So, how much of the revenue in the segment is drug production in your own J.PODs at the moment versus actually already high margin licensing revenue. And you spoke about the high growth with non-Sandoz customers. Can we assume this is mostly licensing revenue or is this potentially production revenue in the red one side?

And I would have actually thought that the undle ramp up would, by now be the majority of the growth. Will this be more meaningful in the second half of the year? Or how should we think about the Sandoz ramp up contribution for this year? And then, sorry, just the last confirmation, for the J.Pod, I think, the to this one you had indicated in the past that The revenue number when it would be fully utilized would probably be around $300 million or around the CapEx that you spend for it if you could just confirm that for us.

Thank you.

Thanks, and, on the mix, the question around drug product versus licensing, The Deals that we do are not today, like, you either buy a license or you buy the product. It's a package today and that's also how we do our contracts and deals. So you get the access to the license for the contracts that we have with our partners and as part of that there is development and we needed also production.

So we're not splitting this out. So right now, there is not a product line for tech licensing and a product line for the product as such. I guess, what you've heard me saying is that we want to give more weight, into the individual components going forward. And that's the right thing to do because we believe.

We can sell both as an integrated offer. We can sell it both as a standalone. But we have not fully explored it in the past, so I can't give you a number. But there will be more emphasis going forward on the individual parts.

With regard to the number piece, Paul, do you want to.

Yeah, just a couple of follow-ups there, Fynn. So as you, as Christine said, in terms of the mix, existing package today, we're looking to monetize our assets fully. So, we see an improving mix, as we look forward for the business. When you think about the non-Sandoz, customers and, the growth that we've seen in the first half, I think it's fair to assume that there's, that is predominantly development and production revenue, versus a sizeable license element at this point in time.

And then as I look out, as your question pertains to kind of my comments on Sandoz in the first half, well, as we have some level of, variability with each of our customers as we progress milestones, and I would expect the same, going forward as part of, our normal business.

Okay, great. And sorry, on the EUR300 million CapEx for the J.Pod, could you confirm that this is roughly the size of revenue that we should think about for the?

What yeah, what I would say is, when we think about the consideration that we've got for the site, based on current book value, we would expect that to exceed current book value.

Christian Ehmann, Warburg Research.

Hello everyone and thanks for taking my question. I'm trying to piggyback on my previous colleague's question. So could you help us understand the rationale to now consider a sale of the J.POD two in Toulouse? At this point in time, so just before, or at least once you finished building up the asset and then considering a sale, I would really like to get a sense what the more detailed, let's say rational is for the sale.

Thanks, Christian for the question and apologies if I repeat a couple of messages here, but it's just exactly following our strategy. We've, reviewed, where we want just to be in the future. We've communicated this in April, and we're now executing. So, it is exactly the right timing, and, it's actually not much more to say about it.

Joseph Hedden, RX Securities.

Good afternoon and thanks for taking my questions. I'm just interested to dig in a little on your efforts on enhancing the DPD offering for kidney diseases, and perhaps some metrics. So it would be helpful to understand what proportion of current revenues come from projects in the kidney disease space and where do you expect that to be around the time of your mid-term outlook in 2028.

Thank you.

Thanks a lot. This goes straight to the Cord as well.

So, a core piece, or let's let me start this way. We believe that you think that, really very important decisions in the drug discovery process are, of course, made in the pre-clinic. And one of the most important decisions you can make, here is to identify a target that you believe is relevant for a particular. Disease disproportion, in patients.

And, this is a field that, is gaining more and more traction and interest, all over the industry, I would say with the event of Omics technologies and here meaning not just genome analysis or genome sequencing, but in particular.

The profiling of disease relevant tissues down to single-cell resolution level, and particularly using transatomics allows us to have a deeper view into disease relevant mechanisms that are driving disease processes and thereby, identity. Finding novel targets that have the potential to very significantly interfere with the disease, with disease progression in patients and have a disease modification effect, maybe even leading up to a cure.

So we continue to invest into this field. We have shown in the past that through our investments into the deep profiling of kidney disease patients that we were able to strike very interesting partnerships, in chronic kidney diseases with really top-notch, pharma partners such as [Baya], such as [Lili, Noble, Novartis], etc.

And, we continuously keep following the strategy now to go beyond chronic kidney diseases, most recently into acute kidney injury, but, as we have announced last year also in obesity and in eye essentially. So this is a continuous strategy and it's, we intend to follow this going forward and, we believe that these insights, will not, in the doctors in molecular disease mechanisms will not only be helpful in identifying targets, but they will be extremely helpful also in tracking the profiles of drug candidates through the pre-clinic and even into the clinic.

So the most advanced molecule we currently have out of these efforts, is currently in Phase 1 together with payer, and, we are very excited about this program. We believe this program will be going moving forward in the future. And there will be many more to come and follow this task.

So generally, we feel that this is a very, a high-value strategy for Evotec. It really speaks to the strength of Evotec in running integrated drug discovery programs as real partners. In the pharmaceutical industry and, based on this, we want to continue and this, involves, of course, AI-driven drug discovery. It involves, no, it involves all of these components that we can bring to bear on these programs.

I hope that helps a little bit.

Yes, thanks, and perhaps if I could just have one more, related to the questions and comments that we've already had on just, and specifically the broadening of the customer base. I'm just interested what types of customers are you seeing these foundations, biotech, large father, and. Are these all development work packages that you previously spoke of or some perhaps a bit closer to commercial stage, any color that help thank you.

Yeah, so, all sorts of from small to big, and I think, you also said that. Majority or a big chunk of the growth that we've seen in the first half is actually derived from three large pharma companies. So you actually see that it is cutting across the whole chain from biotech to pharma. Given the current nature, this is not late stage clinical. It's early on.

[David Floorn, DSS Capital]

Hey guys, good morning.

Hey, I wanted to ask, or just say it's good to hear Christian that you mentioned that you're negotiating this deal from a position of strength. Because it it does feel like selling your crown asset near cost and selling and presumably most of your backlog alongside of that.

I know you guys aren't commenting on it, but I really do hope that, from your position of strength that the tail economics, the milestone, the royalties are not just going to be IRR positive but are also going to be close to NPV positive. Because you've already made this big investment, the balance sheet's not in bad shape and you've done almost all the hard work here.

So are you also thinking about it from an NPV basis?

If it, if that's a question we can say yes to it.

Alright, great, that's great and then this big pivot and strategy. It seems like the most attractive components of just, outside of, the technological advances are you guys can do the small batches which lend yourself or position yourself well to do a lot of FIH work and hopefully, I thought the strategy was always, lock up these biotechs, hopefully some pharmas.

Early in the program because once, the, these, programs are moving through towards commercial launch, the switching costs are way too high. And so, you basically once you have them early as long as they're successful, you have them for life. But this seems like, this pivot, it's unclear to me like if you're kind of maybe not ostracizing but making it more difficult to get bio-tech.

Partnerships Simply because they don't want to, most of them are fairly cash strapped. They don't want to commit a ton of capital towards, building a manufacturing capacity. And if you're trying to sign up with them later or get them to commit to your after life strategy. It'll be too late in their development progress and they're not going to want to switch to you later on. So, I, I'm just curious if this asset light model really only works with generics and large pharma and if there's a pivot away from like, trying to lock up a lot of early stage biotech as well.

Thanks, David. And you probably will assume we've thought this through well. You're right. FIH is important and it will remain important. The technology works well with complex molecules and it works well with high density need. So we know that we have excellent sweet spot for certain type of products and obviously the CapEx [light] model doesn't mean that we cannot provide.

Capacity for those biotech companies. Keep in mind we've shown a picture with a large facility in the US. Facility where we can continue to provide manufacturing capacity to this biotech. We can expand and we can find alternative models to provide capacity. So this is definitely not a change in our strategy. And it definitely does not hamper our ability to bring also this part of the business to Evotec.

All right, great. So it's not keeping [Redmond], which I thought, had a maximum capacity of a couple strains. I didn't think you could keep growing that. I just wanted, I didn't know if at some point you are going to say, hey, we're selling Toulouse, but we may end up having to add another J.POD and kind of do, an asset like an asset heavy kind of model pivot back to the asset heavy.

That's definitely not the plan.

All right, and thanks for providing that color on the three large pharma. I thought, my guess and most of it being early stage, I thought the one of them was going to be late stage as you have, a customer, running a couple Phase 3s that you've had. With [povi] --

But yeah, so it does sound nice though that you're getting some early stage, potentially larger scale work with three large farmers that's driving a lot of the success currently.

I, recurring, topic that I unfortunately have on this call, I'd love to talk more about this customer deals. And I, so, the moment, our partner feels. We can jointly talk about it, we will do, but unfortunately, on this topic, we are pretty much handcuffed.

All right. And then the last thing that the the booking slide that you guys have included the last few conference calls, is that going to come back? And I know it's [anecdotal] and it seems to be longer duration than it had been historically, but it was nice to see the progress in discovery bookings.

Are you talking about the the royalty slide?

No, they had a booking slide that had you know that had bookings growth by quarter in the last few slides that was showing year over year growth and you know there was some distortion from the one large contract, but it's nice to see like. Visually, how bookings are progressing because I think everyone on this call is hoping for, to see some sort of sign in the turn in this in discovery business.

Thanks for the hints. It's a bit of a so we've tried to provide you with some leading indicators today when it comes to VC funding. A bit of time I get between the funding, the spending, and then they the booking and then the revenues, but we'll have a look at it, and. I get back on this topic.

Thank you. All right.

Douglas Thao, HC Wainwright.

Hi, good morning. Thanks for taking the question. I'm just curious. I think in the prepared remarks you made a comment that you did see or have seen an increase in change orders and that they were mostly just driven by scientific issues. I was just wondering if you could sort of provide a little more color on that if there was anything thematic, and what would be driving this sort of it sounds like somewhat systematic increase in these exchange orders.

Thank you.

Yeah, thanks, Douglas, and that's exactly what I, would like to avoid that it becomes a message of a systematic, development, but, we also felt that it's an important data point. As I said, mostly scientific reasons. There was a select number of customers with strategic decisions where they were deciding to relocate funds into other projects later stage actually fits well into the message I gave about funding.

There's no concerns here whatsoever about business moving outside of Evotec, and it's fair to say when you look at the pandemic, Fewer projects were killed at an early stage. Currently, there's more scrutiny, but there's absolutely no indication that this is a trend. And that's why I also said when we just look at the beginning of the second half, this trend had, reversed, but I, seriously, I don't want to, come across as if I'm indicating here that this is a trend.

Okay, and just as a follow up, and I appreciate your point, and I was not trying to say suggest it was systematic in terms of sort of increasing occurrence. I guess what I was just curious was if there was some consistency in the types of changes. That you are seeing, is it shifts within therapeutic areas? Is it adoption or preference for different technologies, maybe a philosophical change in terms of how people are pursuing our programs.

And not at all. No pattern here.

As a reminder, if you wish to register for a question, please press star and one on your telephone. We have a follow-up question from the line of Charles Weston from RBC Europe. Please go ahead.

Thanks for extending the call slightly for a couple of quick ones. First of all, we're now halfway through Q3, so Paul, I was wondering if you could give us a sense of what the Q3, Q4, phase in might be, in DPD, which I think tends to be more Q4 weights and also biologics.

Yeah, thanks, Charles. So, as I said earlier, the revenue profile for the full year, for DPD is pretty consistent with the first half dynamics. So we see that, for [EP&D] in the second half to look a little bit like the first half from a growth profile. That said, from the, just business, we see a significant step up in the second half from the 16% growth rate that we've seen in the first half.

And then when you think about the phasing, I would expect, our overall profile to be consistent with what we saw in 2024 with a significant contribution in the fourth quarter.

Thank you. And just one last one on the Sandoz deal. Previously when you did the deal with Sandoz, you indicated that there were obviously supply components, but you also had technology licenses, milestones royalties, etc. Has that, is that bit staying unchanged and you're selling the assets? Is that the way to think about it, or is the whole deal be being renegotiated as part of this?

I think you should think about the Sandoz arrangement to be a holistic arrangement, as we, move to a new chapter in our relationship. So it'll be --

Ladies and gentlemen, that was the last question. I would now like to turn the conference back over to Volker Broun, Head of IR and ESG, for any closing remarks.

Thank you, Matilda. And, we would like to thank all attendees in today's call and hope to see as many, of you as possible at the various conferences in September and October, and look forward to catch up on our next regular results call on the November 5.

Until then, I hope you can enjoy the rest of the summer and, thank you. Goodbye.

Ladies and gentlemen, the conference is now over. Thank you for choosing chorus call and thank you for participating in the conference. You may now disconnect your lines. Goodbye.